Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma, According to Baseline Body Mass Index: Results from the Phase 2b PATHWAY Study

被引：0
|
作者：
Ambrose, Chris [1 ]
Colice, Gene [1 ]
Salapa, Kinga [2 ]
Parnes, Jane [3 ]
Corren, Jonathan [4 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] AstraZeneca, Warsaw, Poland
[3] Amgen Inc, Thousand Oaks, CA USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
075
引用
收藏
页码：AB25 / AB25
页数：1
相关论文
共 50 条
  • [21] Tezepelumab Reduces Exacerbations Across All Seasons In Patients With Severe, Uncontrolled Asthma With Seasonal Allergy: Results From The Phase 3 NAVIGATOR Study
    Corren, Jonathan
    Lindsley, Andrew
    Spahn, Joseph
    Cook, Bill
    Griffiths, Janet
    Martin, Nicole
    Colice, Gene
    Pavord, Ian
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB194 - AB194
  • [22] Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with Respiratory Comorbidities: Results from the Phase 3 NAVIGATOR Study
    Carr, Tara
    Bernstein, Jonathan
    Cook, Bill
    Hunter, Gillian
    Ambrose, Chris
    Llanos-Ackert, Jean-Pierre
    Lindsley, Andrew
    Colice, Gene
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB152 - AB152
  • [23] Effects of tezepelumab on asthma exacerbations, type 2 biomarkers, lung function and asthma control in patients with severe, uncontrolled asthma with and without nasal polyps: PATHWAY phase IIb study
    Emson, C.
    Corren, J.
    Salapa, K.
    Hellqvist, A.
    Parnes, J. R.
    Colice, G.
    ALLERGY, 2020, 75 : 19 - 20
  • [24] The effect of tezepelumab in patients with allergic asthma: Results from the PATHWAY phase IIb study
    Corren, J.
    Colice, G.
    Salapa, K.
    Bowen, K.
    Llanos-Ackert, J.
    ALLERGY, 2020, 75 : 19 - 19
  • [25] Effect of Tezepelumab on Exercise Tolerance in Patients With Severe, Uncontrolled Asthma From the NAVIGATOR Study
    Lugogo, N. L.
    Kraft, M.
    Corren, J.
    Martin, N.
    Shenoy, K. V.
    Shenoy, S. F.
    Chandarana, S.
    Ambrose, C. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [26] Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
    Menzies-Gow, Andrew
    Ambrose, Christopher S.
    Colice, Gene
    Hunter, Gillian
    Cook, Bill
    Molfino, Nestor A.
    Llanos, Jean-Pierre
    Israel, Elliot
    ADVANCES IN THERAPY, 2023, 40 (11) : 4957 - 4971
  • [27] EFFECT OF TEZEPELUMAB ON LUNG FUNCTION IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA IN THE PHASE 3 NAVIGATOR STUDY
    Israel, Elliot
    Menzies-Gow, Andrew
    Colice, Gene
    Ambrose, Christopher
    Hunter, Gillian
    Cook, William
    Molfino, Nestor
    Llanos-Ackert, Jean-Pierre
    CHEST, 2021, 160 (04) : 41A - 43A
  • [28] Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
    Andrew Menzies-Gow
    Christopher S. Ambrose
    Gene Colice
    Gillian Hunter
    Bill Cook
    Nestor A. Molfino
    Jean-Pierre Llanos
    Elliot Israel
    Advances in Therapy, 2023, 40 : 4957 - 4971
  • [29] Tezepelumab demonstrates clinically meaningful improvements in asthma control (ACQ-6) in patients with uncontrolled asthma: results from a phase 2b clinical trial
    Corren, Jonathan
    Parnes, Jane R.
    Wang, Liangwei
    Mo, May
    Roseti, Stephanie L.
    Griffiths, Janet M.
    O'Quinn, Sean
    van der Merwe, Rene
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB80 - AB80
  • [30] EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA GROUPED BY NUMBER OF ADDITIONAL ASTHMA CONTROLLER MEDICATIONS: RESULTS FROM THE PHASE 3 NAVIGATOR STUDY
    Kraft, Monica
    Colice, Gene L.
    Ambrose, Christopher
    Cook, William
    Hunter, Gillian
    Molfino, Eleonora A.
    Martin, Neil
    Roseti, Stephanie L.
    CHEST, 2022, 162 (04) : 11A - 12A
12345